School of Medicine


Showing 41-50 of 125 Results

  • Jeffrey Goldberg, MD, PhD

    Jeffrey Goldberg, MD, PhD

    Blumenkranz Smead Professor

    Current Research and Scholarly InterestsLab research on molecular mechanisms of survival and regeneration in the visual system; retinal development and stem cell biology; nanoparticles and tissue engineering. Clinical trials in imaging, biomarker development, and neuroprotection and vision restoration in glaucoma and other neurodegenerative diseases.

  • Mary Elizabeth Hartnett, MD

    Mary Elizabeth Hartnett, MD

    Michael F. Marmor, M.D. Professor of Retinal Science and Disease and Professor of Ophthalmology

    BioMary Elizabeth Hartnett, MD, is the Michael F. Marmor, M.D. Professor in Retinal Science and Diseases and is a Professor of Ophthalmology at Stanford University. Dr. Hartnett is the director of Pediatric Retina at Stanford University and principal investigator of a retinal angiogenesis laboratory, in which she studies causes and treatments for diseases including retinopathy of prematurity and age-related macular degeneration. She created the first-ever academic textbook on the subject, Pediatric Retina, in its third edition, which has proven to be an invaluable resource for residents and ophthalmologists internationally.

    Dr. Hartnett’s NIH-funded laboratory of vascular biology and angiogenesis has studied mechanisms causing pathology in age-related macular degeneration (AMD) and retinopathy of prematurity (ROP). Her work in AMD has been to understand the mechanisms involved in activation and invasion of choroidal endothelial cells anterior to the RPE in order to maintain vasculature that is physiologic and not damaging beneath the RPE. Her lab has elucidated environmental stressors that lead to scarring in the macula for which no vision improvement is currently possible. The goal is to find methods to prevent the scarring.

    Her lab’s work in ROP provided the proof of concept to regulate an angiogenic signaling pathway by inhibiting VEGF to facilitate intraretinal neovascularization as well as to inhibit abnormal extraretinal neovascularization and reduce retinal destruction used in previous treatments. Her work has been translated through clinical trials to lead to new treatments for severe ROP and has represented a paradigm shift in the understanding and treatment of severe ROP.

    Dr. Hartnett has received numerous awards, including the Weisenfeld Award, the highest award for clinician-scientists given by the Association for Research in Vision and Ophthalmology (ARVO), in 2018, and is an ARVO Gold Fellow. She received the 2019 Paul Kayser/Retina Research Foundation Global Award, the Macula Society’s 2016 Paul Henkind Award and its 2019 Arnall Patz Medal, the Paul Kayser/RRF Global Award from the PanAmerica Society, and the 2021 Suzanne Veronneau-Troutman Award, the most prestigious award from Women in Ophthalmology. In 2022, she was one of six at the University of Utah to receive a distinguished research award, for Pediatrics and Ophthalmology.

    Dr. Hartnett's prolific publication record includes 227 articles in peer-reviewed journals and over 40 book chapters. She has delivered numerous national and international invited lectures. Her long list of professional committee work includes serving as chair of the Publications Committee of ARVO, as a mentor for the ARVO Leadership Development Program, and in leadership positions internationally as chair of the research advisory committees for The Macula Society and the Jack McGovern Coats Disease Foundation as well as Chair of the Credentialing Committee for The Retina Society. She reviews manuscripts for more than 20 eye and science journals and serves on the editorial boards of PlosOne, Molecular Vision, and the American Journal of Ophthalmology. Dr. Hartnett is a Fellow of the American College of Surgeons (FACS) and a Silver and Gold Fellow of the Association for Research in Vision and Ophthalmology (FARVO).

  • Natalie Anne Homer, MD

    Natalie Anne Homer, MD

    Assistant Professor of Ophthalmology

    BioDr. Homer completed her ophthalmology residency at Massachusetts Eye and Ear Infirmary at Harvard Medical School and subsequently received fellowship training in plastic and reconstructive surgical procedures of the eyelids, orbit, nasolacrimal system and face accredited by the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) at TOC Eye and Face in Austin, TX. She completed an additional fellowship year in facial cosmetic surgery through the American Academy of Cosmetic Surgery (AACS), training in procedures including rhytidectomy (facelift), platysmaplasty (necklift), forehead/brow lift, blepharoplasty (upper and lower eyelid lift) and autologous fat transfer. She served as an assistant professor in the UC Davis Department of Ophthalmology from 2020 – 2022.

    Dr. Homer clinically provides comprehensive ophthalmic plastic and reconstructive surgical care to her patients. She also enjoys improving patient confidence and self-esteem through restorative cosmetic facial surgery. In addition to clinical care, Dr. Homer strives to educate and inspire young medical trainees as an assistant professor of ophthalmology. Dr. Homer was the recipient of the UC Davis Ophthalmology Surgical Teaching Award in 2022. Dr. Homer serves on the American Board of Ophthalmology Written Examination Development Committee and is an oral board examiner for the American Society of Ophthalmic Plastic and Reconstructive Surgery.

    Dr. Homer has performed research in the areas of orbital oncology, orbital and facial trauma, periorbital infections, eyelid and facial reconstruction, facial nerve palsy, pediatric orbital and adnexal disorders, nasolacrimal surgery, thyroid eye disease, cosmetic and functional surgical outcomes, wound healing, and oculoplastic fellowship education. She has presented her work at national and international conferences. In addition to her scientific work, she published 6 invited articles on topics including the women in cosmetic surgery, ophthalmology advocacy and oculoplastic fellowship training. Administratively, she serves as an Editorial Board Member for the American Journal of Ophthalmology case reports and EyeWiki.

  • Yang Hu, MD, PhD

    Yang Hu, MD, PhD

    Associate Professor of Ophthalmology

    Current Research and Scholarly InterestsThe ultimate goal of the laboratory is to develop efficient therapeutic strategies to achieve CNS neural repair, through promoting neuroprotection, axon regeneration and functional recovery.

    More specifically, we study retinal ganglion cell (RGC) and optic nerve in various optic neuropathies including traumatic, glaucomatous and inflammatory optic nerve injuries to fully understand the molecular mechanisms of CNS neurodegeneration and axon regeneration failure.

  • Michael S. Kapiloff, MD, PhD

    Michael S. Kapiloff, MD, PhD

    Reinhard Family Professor, Professor (Research) of Ophthalmology and, by courtesy, of Medicine (Cardiovascular Medicine)

    Current Research and Scholarly InterestsDr. Michael S. Kapiloff is a faculty member in the Departments of Ophthalmology and Medicine (Cardiovascular Medicine) and a member of the Stanford Cardiovascular Institute. Although Dr. Kapiloff was at one time a Board-Certified General Pediatrician, he is currently involved in full-time basic science and translational research. His laboratory studies the basic molecular mechanisms underlying the response of the retinal ganglion cell and cardiac myocyte to disease. The longstanding interest of his laboratory is the role in intracellular signal transduction of multimolecular complexes organized by scaffold proteins. Recently, his lab has also been involved in the translation of these concepts into new therapies, including the development of new AAV gene therapy biologics for the prevention and treatment of heart failure and for neuroprotection in the eye.

    URL to NCBI listing of all published works:
    http://www.ncbi.nlm.nih.gov/sites/myncbi/michael.kapiloff.1/bibliography/40252285/public/?sort=date&direction=descending

    For more information see Dr. Kapiloff's lab website: http://med.stanford.edu/kapilofflab.html

  • Khizer Khaderi MD, MPH

    Khizer Khaderi MD, MPH

    Clinical Associate Professor, Ophthalmology

    BioDr. Khizer Khaderi is a Clinical Associate Professor at the Byers Eye Institute at Stanford University. Khaderi is the Founding Director of the Stanford Human Perception Laboratory (HPL) and the Stanford Vision Performance Center (VPC). He also serves as faculty at the Stanford Institute for Human-Centered AI and the Wu Tsai Human Performance Alliance (HPA)

    Khaderi is a renowned Neuro-Ophthalmic surgeon, technologist and futurist. Dr. Khaderi is pioneering the field of Symbiotics, defined as the convergence of human science + computer science to design and develop human-centric technologies. Khaderi has extensive domain expertise in artificial intelligence (AI), spatial computing (virtual reality (VR), augmented reality (AR), mixed reality (MxR)), wearables, gaming, IoT, Web3, applied neuroscience, human factors, and human-machine interfaces/interaction. His research interests include developing personalized human intelligent systems based on the human brain and sensory systems, developing technologies to optimize human performance, and combining biological and computational principles to expand our capabilities in research, clinical practice, and everyday life. Dr. Khaderi's approach to advance research interests and develop practical applications for everyday use is building technology, companies and collaborative partnerships across academia and industry.

    Dr. Khaderi’s experience across industry sectors include consumer electronics, gaming, retail, life science, sports/Esports health care, Pharma, e-commerce, to name a few. He has developed novel technologies in these areas, and generated multiple invention patents. Selected as a “40 under 40”, he contributed to President Obama’s Council of Advisors on Science and Technology regarding vision technology and the aging population. He also advises multiple companies, venture firms and organizations including the Global Esports Federation, Magic Leap, Riot Games, Intel, Activision, Unity, Epic Games, Google, FB, Microsoft, Apple, NBA, Aerie Pharma, the World Health Organization, and the World Bank.